We previously reported that intracerebroventricular administration of 6, 7, , a cofactor for aromatic amino acid hydroxylases and nitric oxide synthase, induces an increase in DOPA levels (as an index of DA biosynthesis) and in levels of DA metabolites (as an index of DA release) in the rat brain: the increase in DOPA levels was larger than that of DA metabolites, indicating that 6R-BH 4 enhances DA release. In the present study, we examined the effects of 6R-BH 4 on DA release in vivo from the striatum of male Wistar rats and its mechanism of action using brain microdialysis. When various concentrations of 6R-BJL, 6S-BJL (a diastereoisomer of 6R-BH 4 ) or 6-methyltetrahydropterin (6-MPJL) were added to the perfusion fluid of microdialysis probes, DA levels collected in dialysates increased in a concentration-dependent manner: the 6R-BJL-induced increase was far greater than the increase induced by 6S-BH4 or 6-MPJL. Biopterin had little effect on the DA levels. After i.p. injection of250 mg/kg ofa-methyl-p-tyrosine (a-MT; an inhibitor of tyrosine hydroxylase), most of the 6R-BH 4 -induced increase persisted but the increase induced by 6S-BJL or 6-MPH4 was abolished. The 6R-BH4 -induced increase in DA levels in dialysates was abolished after addition of tetrodotoxin (50 J.1M) to the perfusion fluid, but it persisted after i.p. injection of 100 mg/kg of nomifensine which completely inhibited DA reuptake. The increase in DA levels also persisted after administration of nitric oxide synthase inhibitors. The 6R-BJL-induced increase in DA levels was inhibited by co-administration of 6S-BJL or 6-MPJL. Administration of sepiapterin (an immediate precursor of 6R-BJL) increased tissue levels of reduced biopterin (mainly consisting of 6R-BJL) but not its extracellular levels monitored by brain microdialysis, indicating that it selectively increases the intracellular 6R-BJL levels. In contrast, administration of 6R-BH 4 increased both tissue levels of reduced biopterin and its extracellular levels, indicating that it increases both the intraand extra-cellular 6R-BH 4 leveles. DA levels in dialysates was elevated following administration of sepiaterin (an immediate precursor of 6R-BJL), but the elevation was abolished after pretreatment with a-MT. Furthermore, 6R-BJL increased firing rates of neurons in the dorsal motor nucleus of vagus monitored by a slice patch method. These results suggest that 6R-BJL has a DA releasing action independent of its cofactor for tyrosine hydroxylase and nitric oxide synthase, which is mediated by a specific recognition site for 6R-BH4 on DA neurons or related cells.
Introduction
6R-L-erythro-5,6,7,8-Tetrahydrobiopterin (6R- § Author to whom conespondence should be addressed.
Pteridines/ Vol. 6 / No. 4 BH 4 ) is a natural cofactor for tyrosine hydroxylase (1, 2) , a rate-limiting enzyme for biosynthesis of catecholamines such as dopamine (DA), noradrenaline and adrenaline, and also a cofactor for tryptophan hydroxylase (3), a rate-limiting enzyme for biosynthesis of 5-hydrox~tr\'ptamine \.;;-HT). Because the concentration of 6R-BH 4 in the brain (4-7) is low compared with the Michaelis constants (Km values) of tyrosine hydroxylase (8) (9) (10) (11) (12) (13) and tryptophan hydroxylase (9, 14) for 6R-BH 4 , tissue levels of 6R-BH 4 are considered to regulate the activities in vivo of thess enzymes. Our previous findings that intracerebroventricular administration of 6R-BH4 resulted in enhanced hydroxylation of tyrosine and tryptophan in the rat brain (15) supported this possibility. In the same report (15) , we have noted even larger increases in the content of metabolites of DA and 5-HT, which is considered to be index of the activities of DAergic and 5-HTergic neurons. Furthermore, administretion of 6R-BH 4 has been reported to improve clinical symptoms of malignant hyperphenylalaninemia (16) and Parkinson's disease (17) , in which the activities of catecholamine and/or 5-HT-containing neurons in the brain are decreased because of decreased biosynthesis of catecholamine and/or 5-HT (18, 19) . These data, taken together, suggest that 6R-BH 4 enhances release of catecholamine and/or 5-HT from nerve terminals.
On the other hand, it is now accepted that 6R-BH4 is also a cofactor for nitric oxide (NO) synthase (20) (21) (22) and evidence is accumulating that indicates that NO is involved in modulation of neurotransmitter release (23, 24) .
In the present study, we show a novel DAreleasing acton of 6R-BH 4 which is independent of its cofactor activities for hydroxylases of tyrosine and tryptophan and for NO synthase, using mainly brain microdialysis.
Materials and Methods

Brain microdialysis
Brain microdialysis was performed as described previously (25) (26) (27) . Briefly, under ether anesthesia, a microdialysis probe (BDP 21-03, EICO..\1. Kyoto, Japan) was implanted in the striatum of male Wistar rats weighing 250-300 g (coordinate, :.1 ken from the bregma and the sagittal suture \'-lth the skull flat: A, 2.0; L, 3.0; V, -5.5 mm) and v,as fixed in place with cranioplastic cement . T h~ probe was continuously perfused at a flow rat~ of 9.5 J.ll/min with Ringer's solution (147 m"\1 NaCI, 4 mM CaC1 z , 2.3 mM KCI) and dialysates were collected every 20 min.
After DA levels in dial\'sates had reached a 
Assay of DA in dialysates
Assay of DA collected in dialysates was, in principle, similar to the method described previously (28, 29) but was modified to be suitable for a small volume (27, 30, 31) . After addition of ioo J.lI of 0.1 M perchloric acid containing I mg/ml of sodium bisulfite, I mM EDTA and 20 mg of activated alumina to the dialysate, the pH of the mixture was adjusted to 8.3-8.4 with I M Tris-HCI buffer (pH 8.6) and the mixture was vigorously shaken for 20 min. After washing of alumina three times with distilled water, DA was eluted with 250 J.lI of 0.1 M perchloric acid containing 100 J.lM EDTA. An aliquot of the eluate was analyzed for DA using HPLC with electrochemical detection.
Determination of the concentration of 6R -BH4 in the striatum and the extracellular fluid
Biopterins in the striatum were extracted as described (15, 29) . For determination of reduced biopterin levels in the extracellular fluid, the striatum was dialyzed with a double-barrelled probe (BDP-I-8-03W, ElCOM) instead of the U-shaped probe. The probe complex consisted of two 1-shaped probes glued to each other: the distance between two tips was about 0.4 mm. After implantation of the probe complex in the striatum, each probe was independently perfused: one probe was perfused with Ringer's solution containing pteridines for their administration, and the other with Ringer's solution alone for sampling of extracellular reduced biopterins. The biopterins in the striatal extract and the dialysates ware determined using HPLC with fluorescence detection as described elsewhere (15, 29) The reduced biopterin (mainly consisting of 6R-BH 4 ) was calculated by subtracting oxidized bipopterin from total (reduced+oxidized) biopterin. (32, 33) . Briefly, Wistar rats (16-23 days after birth) were sacmced under ether anesthesia, and a block of the medulla oblongata containing the nucleus was immediately isolated and placed in ice-cold Krebs-Ringer solution. The Krebs-Ringer solution contained (in mM): 113 NaCI, 3 KCI, 1 NaH z P0 4 , 25 NaHCO h 2 CaCl z , 1 MgCl z and 11 glucose. The block was glued to the bottom of a cutting chamber of a vibrating slicer (Dohsaka, Japan), and cross-sectional slices of 120 J.lm thickness containing the dorsal motor nucleus of vagus were made at the level of area postrema. The slices were mounted in a glass-bottomed recording chamber on a microscopic stage, immobilized with nylon threacis attached to a U -shaped platinum frame, and continuously perfused with oxygenated Krebs-Ringer sohHion at a flow rate of 2.2-2.5 ml/min. Neurons in the dorsal motor nucleus of vagus were visualized with Normarski optics (Zeiss) and whole-cell recordings were made with thin-wall borosilicate glass patch pipettes (resistance, 3-5 MQ). The composition of the pipette solution was (in mM): 135 KCI, 2 MgCI 2 , 0.2 EGTA, 5 Hepes (pH 7.3, adjusted with KOH). Experiments were performed under current-clamp conditions using an EPC7 patch clamp amplifier (List, Darmstadt, Germany), and data were analyzed using pClamp software package.
Materials
6R-BH 4 dihydrochloride, 6S-BH4 dihydrochloride and L-erythro-biopterin (biopterin)
were generous gifts from Suntory Institute for Biomedical Research, Osaka, Japan, 6-Methyl-DL-5, 6,7,8-tetrahydropterin (6-MPH 4 ) dihydrochloride was purchased from Sigma Chemical, St.Louis, MO, U.S.A. Nomifensine was a generous gift from Hoechst pharmaceuticals, Frankfurt, Germany
Statistical analysis
All results were expressed means ± SEM. The data were subkected to a two-way analysis of variance, and when significant were encountered, Newman-Keuls' multiple-range test was used to test for significant differences between treatment means. A probability level of p < 0.05 was considered statistically significant.
Results and Discussion
Figuer. 1 shows the effects of 6R-BH4' 6S-BH4 and 6-MPH 4 added to the perfusion fluid on the 175 extracellular DA levels monitored in vivo brain microdialysis. Following addition of various concentrations of 6R-BH4' DA levels collected in dialysates increased in a concentration-dependent manner, and the maximal DA level was obtained at 1 mM, which was about eightfold greater than control values (Figure lA) . Likewise, 6S-BH4 ( Figure IB ) and 6-MPH 4 ( Figure lC) induced concentration-dependent increases in DA levels in dialysates, but the increases were far smallar than that induced by 6R-BH 4 . These results indicate that either of the pteridines enhances DA release. In contrast, biopterin (an oxidized form of 6R-BH 4 ) had little effect on DA levels in dialysates, when it was added to the perfusion fluid at a final concentration of 1 mM (data not shown), indicating that an active form is 6R-BH 4 .
To determine whether the pteridine-induced increase in DA release is secondary to an increase in DA biosynthesis, we examined the effects of pteridines on DA levels dialysates after i.p.injection of 250 mg/kg of a-methyl-p-tyrosine (a-MT), an inhibitor of tyrosine hydroxylase (Figure 2) . In separate experiments, this dose of a-MT was found to completely inhibit tyrosine hydroxylation in vivo and hence DA biosynthesis, before and after administration of pteridines (27, 30, 31) . Even after pretreatment with a-MT, 6R-BH 4 induced an increase in DA levels in dialysates, which amounted to 70% of control values in the absence of administration of a-MT ( Figure. 2A ). In contrast, the increases induced by 6S -BH4 ( Figure 2B ) and 6-MPH 4 ( Figure 2C ) were completly blocked by pretreatment with a-MT. These data taken together show that enhancement of DA release by 6S-BH4 and 6-MPH 4 is totally dependent on an increase in DA biosynthesis, which in turn results from increased availability of the cofactor for tyrosine hydroxylase. In contrast, most of the enhancement of DA release by 6R-BIL (the portion which is resistant to a-MT treatment) is independent of an increase in DA biosynthesis and hence, is due to a mechanism different from its cofactor activity for tyrosine hydroxylase.
To test the possibility that the enhancement of DA release by 6R-BH 4 is mediated by increased production of NO resulting from increased availability of a cofactor for NO synthase, we ex- Open circles represent the control group, in which the striatum was dialyzed without addition of pteridines. Each value is the mean ± SEM of four determinations .
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6S-BH4 in dialysates which was comparable to that in its absence (30) , indicating that the action of 6R-BH 4 is not due to its cotactor activity for NO synthase.
The recovery of 6R-BH 4 through the dialysis membrane determined in vitro was 3.1 ± 0 .3%
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(n = 4). Therefore the concentration of 6R-BH 4 in the vicinty of the dialysis probe was estimated to be around 30 JlM, when the concentration of 4 in the perfusion fluid was 1 mM. On the other hand, the concentration of 6R-BH. within DA nerve terminals is assumed to be around 100 ~M (6) . These data suggest that exogenous 6R-BH 4 can act at the physiological concentration range. The 6R-B~-induced increase in DA levels in dialysates was dose-dependently inhibited by tetrodotoxin (a blocker of voltage-dependent Na+ channels in neuronal tissues) added to the perfusion and almost completely blocked at 50 ~M ( Figure  3) , indicating that the 6R-BH 4 -induce DA release is dependent on neuronal activity. To examine whether the 6R-BH 4 -induced increase in DA levels in dialysates is due to inhibition of reuptake of DA into nerve terminals, we tested the effects of 6R-BH 4 on DA release aftu inhibition of DA reuptake by nomifensine. Following intraperitoneal injection of various doses of nomifensine, DA levels in dialysates increased dose-dependently and reached the maximal level at higher than 100 mg/kg (Fiegure 4), indicating that DA reuptake is completely inhibited at these doses. When 6R-Ba was added to the perfusion fluid after pretreatment with nornifensine ( 100 mg/kg), DA levels in dialysates further increased 
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Time (min) Figure 3 . Effects of varying concentrations of tetrodotoxin (TTX) on 6R-BIL-induced increases in DA levels in striatal dialysates. After DA levels in striatal dialysates reached a steady state, TTX was added to the perfusion fluid of rnicrodialysis probes at a final concentration of 20 ~ (filled triangles), or 50 j.1M (filled circles) during the time indicated by a hatched bar. Sixty minutes after addition of TTX , 6R-BIL was added to the perfusion fluid at a final concentration of 1 mM as indicated (a black bar ). Empty circles represent the control group, which was gi\'en 6R-BH., alone. Each value is the mean ± SE1\.1 of to ur determinations .
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( Figure 4 ). This result indicates that the 6R-BH 4 - induce increase in DA levels in dialysates is not the result of inhibition of DA reuptake but the result of an increase in DA release itself.
To clarifY whether 6R-BH 4 acts inside the cell or from the outside of the cell, we attempted to elveate selectively the intracellular concentration of 6R-BH 4 by administering sepiapterin, which is converted to 6R-BH 4 via me salvage pamway of 6R-BH 4 biosynthesis (34). First we examined the changes of reduced biopterin levels in both the striatal tissue and dialysates following administration of sepiapterin or 6R-BH 4 ( Figure 5 ). During continuous infusion of sepiapterin at 1 mM for 140 min, tissue levels of reduced biopterin (consisting mainly of 6R-BH 4 ) in the striatum markedly increased ( Figure SA) . Infusion of 6R-BH4 at 1 roM also increased tissue levels of reduced biopterin to the comparable extent to that of sepiapterin ( Figure SA) . Similarly, reduced biopterin levels in dialysates were elevated following addition of 6R-BH 4 to the perfusion fluid at 1 mM ( Figure SB) . In contrast, changes of reduced biopterin levels in dialysates were negligible fol- Following infusion of sepiapterin to the perfusion fluid at 1 mM, DA levels in dialysates markedly increased ( Figure 6 ). Unlike the 6R-B~-in duced increase, the sepiapterin-induced increase was abolished after pretreatment with a-MT. These results indicate that enhancement of DA release by sepiapterin is secondary to an increase in DA biosynthesis which results from increased availability of the cofactor for tyrosine hydroxylase.
Considering that the intracellular concentration of 6R-BH 4 is selectively elevated following administration of sepiapterin, it follows that intracellular 6R -BH4 acts exclusively as a cofactor for tyrosine hydroxylase. Conversely, administration of 6R-BH 4 induces both an increase in the extracellular concentration of 6R-BH 4 and an increase in DA release which is independent of DA biosynthesis. These data strongly indicate that 6R-BH4 acts from the outside of the cells to Time (min) Figure 6 . Effects of sepiapterin added to the perfusion fluid on DA levels in dialysates. Twenty minutes after i.p administration of saline (filled cicles) or 250 mg/ kg of a-MT (filled triangles) , sepiapterin (1 mM) was added to the perfusion fluid during the time indicated by a bar. Empty circles represent the control group which was given 250 mg/kg of a-MT alone . Each valu e is the mean ± SEM of four deterinations.
.~ 0. stimulate DA release. To get insights into the mechanism of DAreleasing action of 6R-BH4' we tested the effects of 6S-BH4 or 6 -MPH 4 on the 6R-BH4-induced enhancement of DA release (Figure 7 ). To prevent pteridines from stimulating DA biosynthesis, experiments were performed after inhibition of DA biosynthesis by (X.-MT. As described above, 6R-BH4 alone increased DA levels in dialysates. When 1 mM 6S-BH4 or 6 -MPH 4 was co-administered along with 6R-BH4' the 6R-BH4-induced increase in DA levels in dialysates was inhibited to 5% or 30%, respectively. These results indicate that 6S-BH4 or 6-MPH 4 competes with 6R-BH 4 for the same site, although they cannot enhance DA release. From the pharmacological viewpoint, these data indicate that 6S-BH4 or 6 -MPH 4 is a competitive antagonist of 6R-BH 4 . Finally, we directly measured the changes in firing rates of neurons in the dorsal motor nucleus the vagus nerve following administration of 6R-BH 4 ( Figure 8 ) . The firing rates of neurons were markedly increased following administration of 6R-BH4 to the perfusion fluid of the slice at 25 ).lM. This result presents direct evi- dence that 6R-BH 4 stimulates neuronal activities . In summary, we demonstrated that 6R -BH 4 has a novel action independent of its cofactor activities for tyrosine hydroxylase and nitric oxide synthase. That is, 6R-BH 4 acts on a specific target site on DAergic neurons or related cells to stimulate DA release .
